MangoRx vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent research·How we rank →

MEDVi beats MangoRx overall, scoring 7.7/10 vs 7.5/10. MEDVi is more affordable at $179/mo vs $299/mo. Choose MangoRx for needle-phobic users who want oral-only glp-1 tablets from a . Choose MEDVi for users who want a low entry price with oral and injectable co.

A side-by-side look at MangoRx and MEDVi to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

MangoRx

#26 of 52

7.5/10

Multi-service telehealth platform offering compounded GLP-1 alongside other health services.

Visit MangoRx

Higher Rated

MEDVi

#20 of 52

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Feature	MangoRx	MEDVi
Our Score	7.5/10	7.7/10
Starting Price	$299/mo	$179/mo
Medication Type	Compounded	Both
Insurance Accepted	No	No
Best For	Needle-phobic users who want oral-only GLP-1 tablets from a publicly traded company	Users who want a low entry price with oral and injectable compounded options
Ranking	#26	#20
Get started	Visit MangoRx	Visit MEDVi

Pros & Cons Compared

MangoRx

Pros

+Oral dissolving tablets exclusively, zero injections for any GLP-1 option
+Publicly traded on NASDAQ (MGRX), SEC-required financial transparency that private competitors can't match
+Semaglutide tablet includes Vitamin B6 to help reduce nausea during treatment
+Free 100% online consultation with no video call required

Cons

−Oral semaglutide at $299/mo runs 2-3x injectable alternatives ($99-149/mo). The premium only makes sense if needles are a hard no for you.
−Early-stage public company with limited revenue; the same SEC filings that provide transparency also show the financial uncertainty reflected in the stock.
−Oral tablets are the only format, with no injectable option if you want higher bioavailability. If you may switch to injections later, pick a platform that carries both.

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Our Verdict

MEDVi edges out MangoRx with a score of 7.7/10 vs 7.5/10. If budget is your priority, MEDVi starts at $179/mo compared to MangoRx's $299/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility. Choose MangoRx if you want: needle-phobic users who want oral-only glp-1 tablets from a publicly traded company. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.

Still undecided? Editor's Featured Pick

Yucca Health

$146/mo · 7.7/10 · Compounded

If neither MangoRx nor MEDVi feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is Yucca Health. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $146/mo that stays the same at every dose.

Visit Yucca Health→Read our full Yucca Health review